Innovation and growth should drive several biotech and drug stocks higher in 2020, despite political risk around drug pricing, according to Mizuho.
"Overall, we are bullish on the biopharma sector mainly because of the remarkable innovation we are seeing, including in areas such as neuroscience where innovation has historically been tougher to come by," Mizuho said in a note to clients.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: